Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives

ObjectiveThe objective of this study is to conduct a bibliometric analysis on examining the current condition, areas of interest, and rising trends of immunotherapy for osteosarcoma (ITFOS), as well as its importance in associated research domains.MethodsAn extensive collection of academic papers on...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yunxiang Hu, Rui Yang, Shuai Ni, Zefeng Song
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	osteosarcoma immune function immunotherapy immune checkpoint inhibitor targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1485053/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunotherapy of osteosarcoma based on immune microenvironment modulation
by: Heping Lian, et al.
Published: (2025-01-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics
by: BingBing Li, et al.
Published: (2025-02-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Comprehensive analysis of ESCRT transcriptome-associated signatures and identification of the regulatory role of LMO7-AS1 in osteosarcoma
by: Shibing Zhao, et al.
Published: (2025-01-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
by: Nan Zhang, et al.
Published: (2025-02-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

The success of the tumor immunotherapy: neutrophils from bench to beside
by: Meng Zhu, et al.
Published: (2025-01-01)

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
by: Lin Zhang, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies
by: Reza Panahizadeh, et al.
Published: (2025-01-01)

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01)

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies
by: Li-Chun Lu, et al.
Published: (2023-04-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Overcoming immune evasion with innovative multi-target approaches for glioblastoma
by: Hai Su, et al.
Published: (2025-01-01)

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
by: Chalette Lambert-Swainston, et al.
Published: (2025-01-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
by: Man Wang, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
by: Konstantinos Lallas, et al.
Published: (2025-01-01)

Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01)

NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance
by: Shaoyan Shi, et al.
Published: (2025-01-01)

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation
by: Xinjun Lu, et al.
Published: (2024-11-01)

Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population
by: Wang RH, et al.
Published: (2025-02-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
by: Zongfu Pan, et al.
Published: (2025-02-01)

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma
by: Minglei Huang, et al.
Published: (2024-06-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)